Eflornithine Hydrochloride Hydrate/Sulindac

依氟鸟氨酸/舒林酸

Report date: 2023/12/11 17:20:13

Base Information

Drug NameEflornithine Hydrochloride Hydrate/Sulindac
Drug Alias NameEflornithine/sulindac舒林酸/依氟鸟氨酸Sulindac and Eflornithine Hydrochloride HydrateEflornithine Hydrochloride/SulindacFlynpovi +[6] 
ClassificationSmall molecules
Mechanisms of ActionOrnithine decarboxylase inhibitorsCyclooxygenases inhibitors
TargetsOrnithine decarboxylaseCyclooxygenases
Therapy Area/IndicationsPrecancerous ConditionsTrypanosomiasis
Global Approved IndicationsTrypanosomiasis
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Africa
Original Approved Date2001/01/01
Country/TerritoryUnited StatesSouth Africa
CombinationsYes SulindacEflornithine Hydrochloride Hydrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi
Inactive CompaniesOne-Two Therapeutics Assets LtdNational Cancer Institute
Active IndicationsTrypanosomiasis
Inactive IndicationsPrecancerous Conditions

Other Information

ATC CodeP01
Related LinksN/A